Tag: Campylobacter and Enterotoxigenic Escherichia coli
Immuron prepares for diarrhoea-focused clinical trial as US FDA lifts clinical hold
Immuron, an Australia-based biopharmaceutical company, is slated to move forward with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) following approval from the US Food and Drug Administration (FDA).
Featured Article
AI & Manufacturing Month with Australian Manufacturing
As industries around the globe embrace the digital revolution, artificial intelligence (AI) is rapidly transforming the manufacturing landscape.Â
